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include collaboration with other biologic registers.
Nevertheless, the absolute risk appears to be very small.
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Complement activation is a crucial pathogenic
factor in catastrophic antiphospholipid syndrome
Rheumatology key message
. Catastrophic antiphospholipid syndrome is asso-
ciated with excessive complement activation ex-
plaining the clinical efficacy of complement
inhibitory treatment.
SIR, Research suggests that the complement system
plays a role in the pathophysiology of APS, and experi-
mental studies have revealed a requirement for C5 in APS-
induced thrombus formation [1]. However, limited data are
available on complement activation in the potentially life-
threatening catastrophic form of APS (CAPS) [2]. Despite
occasional reports of beneficial clinical effects of the
TABLE 1 Pneumocystis jirovecii pneumonia events in
each cohort
Characteristic sDMARD TNFi
Possible cases, n 4 21
Confirmed cases, n 2 14a
Age at event, mean (S.D.) 65 (0.1) 62 (9.6)




10 (9.9) 11.6 (9.6)




TNFi at time of
event, n (%)




On steroids at event, n (%) 1 (50) 8 (57)
On MTX at baseline, n (%) 1 (50) 9 (64)
Current smokers at
baseline, n (%)
0 (0) 8 (57)
Lung disease at
baseline, n (%)
2 (100) 1 (7)
Outcome, n (%)
Recovered 2 (100) 9 (64)
Died 0 (0) 5 (36)
aAnalysis included only those events that developed while
the patient was receiving TNFi.
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complement inhibitor eculizumab in CAPS [3], the degree
and pattern of complement activation has not been inves-
tigated. Such information is required as a rationale for
therapeutic complement inhibition and is provided in the
present report.
Plasma samples for measurement of complement acti-
vation products (C4bc for the classical and lectin path-
ways, C3bBbP for the alternative pathway, C3bc for the
common pathway and sC5b-9 for the terminal pathway)
were obtained in EDTA tubes, immediately placed on
crushed ice, centrifuged and stored at 80C. The acti-
vation product assays, based on specific monoclonal
antibodies to neoepitopes selectively exposed in the ac-
tivation products, have been described in detail previously
[4]. Routine C3, C4, haematology and biochemical ana-
lyses were performed in the laboratory. Eculizumab was
obtained from Alexion Pharmaceuticals (Lausanne,
Switzerland). Written informed consent was obtained
from the patient.
We present the case of a 34-year-old female patient
diagnosed with APS after several miscarriages and deep
venous thrombosis in 2004. The patient has repeatedly
displayed positive lupus serology (ANA and ENA screen-
ing positive, anti-dsDNA = 50 U/l, ref<10) without clinical
FIG. 1 Complement activation in a patient with CAPS
(A) Complement activation products, native components, and the ratios thereof, were measured in the patient with CAPS
during treatment with eculizumab (arrows along the x-axis refer to eculizumab infusion. Upper panel: sC5b-9; reference
range <600 ng/ml. Middle panel: the ratio of complement activation products and their native components C4bc/C4
(reference range 28140), C3bc/C3 (reference range 718) and C3bBbPb/C3 (reference range 1848). Lower panel: C3
(reference range 0.51.3 g/l) and C4 (reference range 0.10.5 g/l). (B) Concentration of creatinine and urea (arrow: first
infusion of eculizumab). (C) Concentration of lactate dehydrogenase (LD), procalcitonin (PCT) and ferritin (arrow: first
infusion of eculizumab).
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signs of lupus. Recently she was admitted with
Staphylococcus aureus wound infection and sepsis.
Biochemistry revealed anaemia, thrombocytopaenia, hae-
molysis, positive lupus anticoagulant (SCT = 2.6,
ref<1.25; dRVVT = 3.1, ref<2.25) and high aPL (anti-2-
glycoprotein: IgG 62 U/l, IgM 535 U/l; anti-cardiolipin:
IgG>410 U/l, IgM>470 U/l). Her condition deteriorated
dramatically, with respiratory distress, circulatory collapse
and cardiac arrest, requiring resuscitation and intensive
care treatment. Renal function rapidly declined, with
increasing creatinine and urea values (Fig. 1B).
Eculizumab treatment was started, with remarkable clin-
ical improvements within hours. After three days she did
not require respiratory support and the kidney failure
ceased (Fig. 1B). The level of sC5b-9 was exceptionally
high initially, reflecting substantial intravascular comple-
ment activation, but decreased abruptly after administra-
tion of eculizumab (Fig. 1A). Importantly, the levels of
activation product ratios declined and C3 and C4
increased simultaneously, consistent with a substantial
reduction in complement activation upstream to C5 (Fig.
1A). Lactate dehydrogenase, procalcitonin and ferritin
decreased abruptly after administration of eculizumab
(Fig. 1C). Of particular note, eculizumab withdrawal led
to a serious clinical relapse, with pain, tachycardia and
tachypnoea, concomitant with decreased C3 and C4
(Fig. 1A). The triggering factor for this second episode
was apparently a persistent wound infection. However,
eculizumab rechallenge once again rapidly reversed the
symptoms. This indicates that the effect was not coinci-
dental to other treatment or spontaneous remission, but
that there was a close relation between the degree of
complement activation and the clinical course.
The present data elucidates the dynamics of comple-
ment activation and relates it to the clinical course of
CAPS, suggesting complement activation to be an essen-
tial part in the pathophysiology and providing a rationale
for therapeutic complement inhibition in CAPS. Low levels
of C3 and C4 may indicate complement activation with
consumption, but several other factors influence the
protein levels. Thus, the measurement of complement ac-
tivation products is required for documenting in vivo com-
plement activation, and the ratio between an activation
product and its parent protein is a sensitive indicator of
activation. Markedly increased classical and/or lectin
pathway activation was observed from the high C4bc/
C4-ratio. Additionally, the substantial increased alterna-
tive pathway convertase (C3bBbP) and C3bBbP/C3-ratio
reflect that the alternative pathway amplification loop was
highly activated in CAPS. Finally, the terminal pathway
was excessively activated, revealed by the high level of
sC5b-9. The fact that eculizumab inhibits C5 indicates
that the disease process is driven largely by terminal path-
way activation with release of the potent pro-inflammatory
anaphylatoxin C5a and formation of the C5b-9 complex.
This leads to endothelial cell activation, including tissue
factor expression, with subsequent serious fatal thrombus
formation observed in CAPS [5]. Both C5a- and C5b-9
formation is efficiently inhibited by eculizumab [6]. In
conclusion, complement inhibition should be regarded
as an important and possibly life-saving medical interven-
tion for patients with CAPS.
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